BridgeBio Q3 revenue rises to $353.2 million; operating loss narrows to $11.6 million
BridgeBio reported third quarter 2026 total revenues of $353.2 million, up from $120.7 million a year earlier, driven by $253.2 million of U.S. Attruby net product revenue and a one-time $75.0 million Bayer sales milestone. Loss from operations narrowed to $11.6 million from $145.2 million, but net loss attributable to common stockholders was $83.0 million, or $0.42 per share, after $26.3 million in preferred stock dividends and accretion.
Key points
- Total revenues, net of $353.2 million, up from $120.7 million in Q3 2025
- U.S. Attruby net product revenue of $253.2 million; license and services revenue of $79.3 million included the $75.0 million Bayer milestone
- Loss from operations of $11.6 million versus $145.2 million a year earlier
- Cash, cash equivalents and marketable securities of $1.5 billion as of September 30, 2026; BBP-418 PDUFA date is November 27, 2026
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.